YAP1 and lung carcinoma: To examine whether YAP activity also drives doxorubicin‐specific chemoresistance in lung cancer cells, we compared measurements of cell‐line sensitivity to doxorubicin in the CTD2 dataset with the cell‐line oncogenic enrichment scores.